A pretreatment PSA level of 7 to 10 Ng/mL is an independent predictor of adverse biochemical disease free survival among low risk prostate cancer patients treated with I-125 brachytherapy

被引：0
|
作者：
Cesaretti, J. A. [1 ]
Stone, N. N. [1 ]
Kao, J. [1 ]
Stock, R. G. [1 ]
机构：
[1] Mt Sinai Sch Med, New York, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 72卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2008.06.1066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S304 / S305
页数：2
相关论文
共 22 条
  • [1] BIOCHEMICAL (PSA) FREE SURVIVAL AMONG 700 PROSTATE CANCER PATIENTS TREATED WITH I-125 BRACHYTHERAPY ONLY
    Matzkin, H.
    Stenger, A.
    Chen, J.
    Mabjeesh, N. J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 310 - 310
  • [2] Impact of Implantation Technique on Biochemical Disease-free Survival in I-125 Treated Prostate Cancer Patients
    Foster, W.
    Despres, P.
    Martin, A.
    Aubin, S.
    Varfalvy, N.
    Beaulieu, L.
    Vigneault, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S390 - S391
  • [3] Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience
    Nobes, J. P.
    Wells, I. G.
    Khaksar, S. J.
    Money-Kyrle, J. F.
    Laing, R. W.
    Langley, S. E. M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2009, 12 (01) : 61 - 66
  • [4] Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy
    Anna Thi Huyen Tran
    Mandall, Paula
    Swindell, Ric
    Hoskin, P. J.
    Bottomley, David Martin
    Logue, John Paul
    Wylie, James Pinson
    RADIOTHERAPY AND ONCOLOGY, 2013, 109 (02) : 235 - 240
  • [5] Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience
    J P Nobes
    I G Wells
    S J Khaksar
    J F Money-Kyrle
    R W Laing
    S E M Langley
    Prostate Cancer and Prostatic Diseases, 2009, 12 : 61 - 66
  • [6] Relationships between PSA bounce and definitions of biochemical failure following I-125 brachytherapy for localized, low-risk prostate cancer
    Swaminath, A.
    Dayes, I.
    Sathya, J.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S43 - S43
  • [7] The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy
    Vigneault, E.
    Martell, K.
    Taussky, D.
    Husain, S. M.
    Delouya, G.
    Mbodji, K.
    Magnan, S.
    Despres, P.
    Lavallee, M. C.
    Aubin, S.
    Beaulieu, L.
    Foster, W.
    Martin, A. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E271 - E271
  • [8] HIGH-RISK PROSTATE CANCER WITH GLEASON SCORE 8-10 AND PSA LEVEL ≤15 ng/mL TREATED WITH PERMANENT INTERSTITIAL BRACHYTHERAPY
    Fang, L. Christine
    Merrick, Gregory S.
    Butler, Wayne M.
    Galbreath, Robert W.
    Murray, Brian C.
    Reed, Joshua L.
    Adamovich, Edward
    Wallner, Kent E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : 992 - 996
  • [9] Validation of the 2018 NCCN Prostate Cancer Risk Classification among 2,715 Patients Treated with Low Dose Rate I-125 Brachytherapy
    Tom, M. C.
    Reddy, C. A.
    Smile, T.
    Zhang, R. X.
    Ciezki, J. P.
    Stephans, K. L.
    Mian, O. Y.
    Klein, E. A.
    Campbell, S.
    Ulchaker, J.
    Angermeier, K.
    Tendulkar, R. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E310 - E310
  • [10] Biochemical outcomes for patients with intermediate-risk, organ-confined prostate cancer treated with I-125 interstitial brachytherapy monotherapy.
    Anna Thi Huyen Tran
    Mandall, Paula
    Swindell, Ric
    Hoskin, Peter
    Bottomley, David
    Wylie, James
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
123